Introduction: The purpose of the study is to evaluate the efficacy and safety of
| INTRODUCTION
Opioid dependence, most commonly manifested as heroin dependence, remains a serious public health issue in China and other countries in the world (Boyuan, Yang, Ke, Xueyong, & Sheng, 2014; Doosti, Dashti, Tabatabai, & Hosseinzadeh, 2013; Li & Li, 2013; Ling et al., 2010; Ling et al., 2016; Marienfeld et al., 2015; Marsch et al., 2016; Mattick, Breen, Kimber, & Davoli, 2014; Mokri, Chawarski, Taherinakhost, & Schottenfeld, 2016; Rosenthal et al., 2016) . In 2015, 2.3 million people in China were registered drug addicts, 40% of whom were heroin users (China National Narcotic Control Committee, 2016) . Since only a portion of drug users register for treatment, the true number of addicts in China is likely much higher.
Heroin use, frequently injected, is associated with the spread of infectious diseases (eg, HIV, hepatitis B, hepatitis C) and overdose deaths (Li & Li, 2013; Ling et al., 2010; Marsch et al., 2016; Mattick et al., 2014) . Several programs have been instituted to reduce problems associated with the social issues of drug abuse and HIV transmission in China (Li & Li, 2013; Marienfeld et al., 2015) . Limited medications are available in China to treat opioid dependence (Boyuan et al., 2014; Doosti et al., 2013; Li & Li, 2013; Marienfeld et al., 2015) ; new pharmacotherapies may be important in engaging and retaining individuals in treatment and reducing abuse (Li & Li, 2013; Ling et al., 2010; Marienfeld et al., 2015; Marsch et al., 2016) .
More than 10 traditional Chinese medicines have been approved for the treatment of opiate addiction by the Chinese State Food and Drug Administration (SFDA) (Doosti et al., 2013) , but they are only indicated for detoxification. Methadone maintenance treatment (MMT) has been a primary form of treatment for opioid dependence and an integral part of harm reduction programs in China (Marienfeld et al., 2015) ; however, MMT programs require licensed specialty clinics and are associated with risks of overdose-related death (Ling et al., 2010; Marienfeld et al., 2015) , potentially influencing its application.
The lack of efficacious treatment options has led to interest in other pharmacotherapies for opioid dependence treatment. Unlike methadone, which is a full μ-opioid receptor agonist, buprenorphine is a partial μ-opioid receptor agonist and exhibits a pharmacological ceiling effect at opioid receptor sites. These pharmacologic characteristics have contributed to its therapeutic use in treating opioid dependence (Ling et al., 2010; Marsch et al., 2016; Mattick et al., 2014) . The benefits of buprenorphine treatment include reduced overdose risk, easier withdrawal phases, and possible alternate-day dosing due to its longer duration of action. Buprenorphine is effective for the treatment of opioid dependence and is used worldwide (Ling et al., 2010; Marsch et al., 2016; Mattick et al., 2014) .
Buprenorphine has been found to be equally effective as methadone in decreasing opioid abuse, but less effective at retaining opioid-dependent individuals in treatment (Mattick et al., 2014) .
Despite widespread success as a maintenance therapy for opioid dependence (Mattick et al., 2014) , buprenorphine misuse and diversion has been reported (Fiellin et al., 2011; Mattick et al., 2014) . The limitations in these treatment options highlight the importance in finding alternative therapies for China.
Buprenorphine/naloxone formulations contain 2 mg or 8 mg of buprenorphine combined with 0.5 mg or 2 mg of naloxone, respectively. Naloxone is a full-opioid receptor antagonist with poor oral and sublingual bioavailability that, when injected, can rapidly precipitate opioid withdrawal. Naloxone was added to buprenorphine to deter intravenous abuse without affecting the efficacy of the treatment. Studies in Western countries have demonstrated its efficacy in opioid-dependent patients and reduction of intravenous misuse of buprenorphine; limited information exists among the Chinese population (Schottenfeld, Chawarski, & Mazlan, 2008; HIV Prevention Trials Network, 2011; Hoffman, Peyton, & Sumner, 2017; Woody, 2017) .
The current report presents results from a phase 3, multicenter, randomized, placebo-controlled investigation of buprenorphine/naloxone sublingual tablets for treatment of opioid dependence in Chinese adults.
| METHODS

| Research aims and hypotheses
Harmonization Good Clinical Practice (ICH-GCP) guidelines and applicable Chinese regulatory requirements.
| Participants and setting
Patients were recruited from five clinic centers in China between September 2014 and December 2015. The study was approved by independent ethics committees at each center, and written informed consent was obtained from all participants.
The study enrolled Chinese nationals aged 18 to 65 years with an opioid dependence diagnosis (DSM-IV-TR) who were currently using opioids. Full inclusion and exclusion criteria are listed in supplemental materials.
| Study design
This was a multicenter, randomized, double-blind, placebo-controlled outpatient maintenance study comparing buprenorphine/naloxone sublingual tablets with placebo for the treatment of opioid dependence in Chinese participants. A detailed study schema is presented in Table 1 .
Following a 7-day screening period, eligible participants with COWS score ≥ 12 entered a 3-to 5-day open-label induction period during which active study medication (buprenorphine/naloxone) was administered. Following induction, participants were stabilized on therapeutic dosages of buprenorphine/naloxone and were evaluated for randomization based on the following criteria: seven consecutive days with no dose change, very mild or no withdrawal symptoms (COWS score ≤ 4), no illicit opioid use (determined by UDS), and no ancillary medications to relieve withdrawal symptoms. The stabilization period included a 21-day extension to allow participants to meet these criteria. Those who failed to reach stabilization were discharged and referred to locally available treatment facilities.
Stabilized participants were randomized 1:1 buprenorphine/ naloxone or placebo for 6 weeks. Doses matched the dosage from the last day of stabilization and were administered daily at the study site. All participants received weekly counseling sessions during the randomization period. Those who completed the study were tapered off buprenorphine/naloxone over 1 to 2 weeks and administratively discharged; participants who withdrew from the study or could not be tapered off study drug were offered detoxification treatment or MMT per applicable regulations and clinical judgment.
Participants were contacted by phone after the final medication visit for post-medication assessment and follow-up for adverse events (AE), as well as an informal wrap-up counseling session.
Randomization codes were provided to the principal investigator at each site in case emergency access to a participant's medication assignment was needed. To maintain blinding, peppermint mouthwash was used within 5 minutes of sublingual tablet administration to obscure taste differences between buprenorphine/naloxone and placebo. Placebo tablets matched the appearance of active study drugs. For outcome measurement, UDS were conducted by unblinded personnel during the treatment period. 
| Outcomes and instruments
| Determination of sample size
The sample size was determined based on outcomes from previous research (Schottenfeld et al., 2008) and is detailed in the supplemental materials.
| Analysis sets
The Full Analysis Set (FAS) included all randomized participants who received trial drug. The Per Protocol Set (PPS) comprised all participants who satisfied the trial protocol and completed the clinical observation period. In addition to analyses of data from all patients who completed the study, intention-to-treat (ITT) analyses of efficacy endpoints were conducted with all randomized patient data. All randomized participants who received at least one dose of study drug were used for safety analysis.
| Statistical analyses
Between-group comparisons of the primary efficacy measure (retention in treatment) were made using a Kaplan-Meier survival analysis to derive estimates and Cox regression proportional hazard ratios for pair-wise comparisons. An overall comparison of the difference in time to treatment failure was analyzed using analysis of variance (ANOVA) and pair-wise comparisons between treatment groups.
Secondary outcome measures, COWS and VAS of heroin craving, were compared between treatment groups using analysis of covariance (ANCOVA). Using the Kaplan-Meier approach to derive estimates, the time to first opioid use and time to treatment completion, last contact or discharge from the study between treatment groups were assessed using survival analysis and summarized by treatment group. A last observation carried forward (LOCF) method was used to process COWS and VAS of heroin craving scores for participants who prematurely terminated treatment during the randomization period.
All AEs that occurred after participants signed the Informed Consent Form (ICF) through final follow-up assessments were included in the safety analysis. Treatment-emergent AEs (TEAEs)-adverse events that emerged during treatment and were not present pre-treatment or worsened relative to the pre-treatment state-were compared between treatment groups using the chi-square test or Fisher's exact test if sample sizes were small. Statistical significance was assessed using a 5% level. 
Day "1" is the randomization day.
b "EOS" is final day of medication, "end of study" in terms of completion of the medication phase ("randomization/treatment period"), whereas "follow-up"
by telephone contact occurs approximately 7 days after EOS.
c Vital signs will be taken after a ≥5-minute rest in the sitting position and will include systolic and diastolic blood pressure, oral temperature, heart rate (beats per minute), and respiration rate (breaths per minute).
d UDS for morphine, methadone, benzodiazepines, ketamine, amphetamine, and methamphetamine. UDS for buprenorphine will be performed only if the participant self-reports use during screening. UDS throughout the trial will be conducted by the site's local laboratory. Study staff and participants will be blind to the results. e UDS will be performed twice weekly at least 3 days apart.
f Urine pregnancy test for women of childbearing potential.
g FSH testing, at screening only, for female participants who are post-menopausal.
h Serum pregnancy testing at screening visit only.
i Serology testing (hepatitis B, hepatitis C, HIV, and syphilis) at screening only.
j Dosing is daily throughout the study. Participants will be provided with 20 mL of peppermint mouthwash to rinse their mouths prior to each dose. In treatment period assess daily COWS and VAS just before dosing (no more than 30 minutes). Repeat COWS 60 minutes after dosing or document patient being free of withdrawal symptoms before leaving clinic.
l Counseling sessions will be once weekly during the randomization/treatment period. The final follow-up assessment will be performed via phone call approximately 1 week after the final medication visit day (day 42) or after early termination to capture any AEs or changes in medications; follow-up may occur within 2 weeks of final clinic visit. 129 in placebo group. Baseline characteristics were similar between the two groups (Table 2). The maximum consecutive days of abstinence from opioids was significantly longer for the buprenorphine/naloxone group compared to the placebo group (P < 0.001). The median maximum consecutive days of abstinence from opioids was: buprenorphine/naloxone, 21 days (95% CI, 26-38); placebo, 5 days (95% CI, 5-8). The Cox hazard ratio (buprenorphine/naloxone versus placebo) was 0.38 (95% CI, 0.25-0.60; P < 0.001).
| Primary efficacy measure: Retention in treatment
| COWS scores
COWS scores were similar between treatment groups prior to dose administration on Day 1 of the randomization period, but significantly lower in the buprenorphine/naloxone group than the placebo group post-dose (P = 0.001). COWS scores before and after dose administration on randomization period Day 7 were significantly lower in the buprenorphine/naloxone group than in the placebo group (pre-dose, P < 0.001; post-dose, P = 0.001). On randomization period Day 14, there was no statistically significant difference in COWS scores before dose administration between treatment groups (P = 0.296), but COWS scores were significantly lower in the buprenorphine/naloxone group following medication administration (P = 0.023). The difference in COWS scores between treatment groups before and after medication administration on randomization Days 21, 28, 35, and 42 was not statistically significant. Using an LOCF method, no differences in COWS scores were observed between treatment groups before medication administration on randomization period Day 1, but were significantly lower in the buprenorphine/naloxone group than in the placebo group for all subsequent study time points (P < 0.001).
| VAS score of craving
There were no significant differences in VAS scores between treatment groups before and after medication administration on randomization period Days 1, 14, 21, 35, and 42 and before medication on Days 7 and 28 (P > 0.05). Post-medication administration VAS scores were significantly lower in the buprenorphine/naloxone group on Day 7 (P = 0.041) and Day 28 (P = 0.0417). When processed using LOCF method, VAS scores before and after medication administration on randomization period Day 1 for both treatment groups were not significantly different; VAS scores at all subsequent time points were lower in the buprenorphine/naloxone group than in the placebo group (P < 0.05).
| Percentage of opioid-negative urine tests
The average number of urine tests (± standard deviation) performed during the randomization period was: buprenorphine/naloxone, 8.43 ± 4.64; placebo, 3.32 ± 3.45; P < 0.0001. The average number of negative UDSs was significantly higher for participants in the buprenorphine/naloxone group compared with the placebo group (7.8 ± 4.71 vs 2.66 ± 3.19, respectively; P < 0.001). The proportion of negative UDSs over total UDSs was significantly higher in the buprenorphine/naloxone group than the placebo group (90.60% versus 85.59%, respectively; P = 0.025).
| Safety
Among the 260 randomized participants, there were no deaths, 2 serious AEs (SAEs; food poisoning and liver cirrhosis), 2 subjects with severe AEs (gallbladder oedema, ascites, hepatic cirrhosis, splenomegaly, diarrhea, and vomiting), and no treatment discontinuation due to an AE. The 2 SAEs occurred during the randomization period and were considered unlikely related to treatment by the Clinical Event Commit- with a high risk of relapse, overdose, HIV transmission, and other adverse consequences; continued treatment and opioid abstinence decrease these risks (Ling et al., 2010) .
The findings of this study are consistent with the results of a study conducted in the United States (Schottenfeld et al., 2008) and with meta-analyses supporting the effectiveness of buprenorphine/naloxone for the treatment of opioid dependence (Johansson, Berglund, & Lindgren, 2006; Minozzi et al., 2011; Woody, 2017) . Taken together, the results of the current study suggest that the efficacy of buprenorphine/naloxone leads to treatment retention and increased opioid abstinence across different populations and settings compared with placebo.
Craving and withdrawal symptoms, which increase the likelihood of relapse (Heinz et al., 2010; Kim, Ham, Hong, Moon, & Im, 2016) ,
were also considered as a basis for efficacy of treatment. Results from this study indicate that opioid withdrawal symptoms were significantly milder in patients receiving buprenorphine/naloxone compared with those receiving placebo. Craving scores were significantly reduced in patients receiving buprenorphine/naloxone compared with those receiving placebo. UDS results during the study period showed that opioid usage was significantly lower in the buprenorphine/naloxone group than in the placebo group.
Opioid dependence and overdose continue to be public health problems in China (Boyuan et al., 2014; Doosti et al., 2013; Li & Li, 2013; Marienfeld et al., 2015) . Treatment programs for opioiddependent patients in China include community drug rehabilitation, forced isolation treatment, community-based rehabilitation, and community MMT. These programs can meet basic treatment demands of registered "dominant opioid-dependent" users (Elkader & Sproule, 2005; Li & Li, 2013; Marienfeld et al., 2015) , but are unable to meet the treatment needs of "hidden opioid users," those who hide and deny drug misuse to protect reputations and avoid punishment. A treatment model is urgently needed to compensate for this need through voluntary treatment at outpatient clinics in China.
Buprenorphine is considered a new opioid rehabilitation medicine in the field of treatment for "hidden opioid users."
When sublingually administered, the mean bioavailability of buprenorphine is 28% to 51% and <10% for naloxone (Elkader & Sproule, 2005) . Accordingly, the ratio of buprenorphine to naloxone in sublingual tablets was designed so that only buprenorphine can exert pharmacological activity upon sublingual administration; in contrast, the low bioavailability of naloxone results in no significant pharmacologic action after sublingual administration. Naloxone does not reduce the bioavailability of buprenorphine (Woody, 2017) ; however, if the buprenorphine/naloxone combination product is intravenously injected, naloxone will produce strong antagonist effects leading to precipitated withdrawal symptoms in opioid-dependent patients using full-opioid agonists. Therefore, the addition of naloxone reduces the potential for intravenous abuse of buprenorphinecontaining sublingual tablets (Fudala, Yu, Macfadden, Boardman, & Chiang, 1998; Handford et al., 2011) .
No clinically significant abnormalities or trends were observed in laboratory values, vital signs, 12-lead ECG, or physical examinations between study groups during treatment. The safety profile for buprenorphine/naloxone tablets in this study is consistent with known safety profile for the product, and no new safety signals were identified.
Several limitations of this study are important to consider: (1) almost all participants in this study were self-selected. Opioid users who self-identify as having a substance use problem and seek treatment may be distinct from those who have no desire to seek treatment or who are forced into treatment by the criminal justice system, and (2) the effect of sublingual buprenorphine/naloxone treatment may vary depending on initial severity of opioid dependence, duration of opioid dependence, or type of opioid. This study was not statistically powered to examine efficacy within subgroups of patients.
In conclusion, buprenorphine/naloxone may be beneficial in treating an opioid-dependent Chinese population. The availability of buprenorphine/naloxone will provide an additional treatment option for opioid dependence in China. The current findings would provide clinicians with more choices when determining the best treatment for an individual with opioid dependence in China.
